INOVIQ's breakthrough in cancer detection

INOVIQ (ASX:IIQ) has announced the successful completion of a patient validation study for its EXO-OC blood test. The test is designed for early ovarian cancer detection and achieved an accuracy of over 94%. This marks a significant advancement in ovarian cancer testing.

INOVIQ's strategic outlook

The successful completion of the independent validation study for INOVIQ's EXO-OC blood test represents a key milestone in ovarian cancer diagnostics. The test demonstrated high sensitivity and specificity, especially in early-stage detection, which is critical for improving survival rates. INOVIQ plans to optimize the test for a commercial instrument platform and conduct further clinical validation. The company aims to eventually deliver the test in clinical settings, leveraging its EXO-NET technology. INOVIQ remains focused on advancing diagnostics for ovarian and breast cancers, with the potential to transform cancer detection and patient outcomes. The global market for ovarian cancer diagnostics is projected to grow significantly, offering substantial market potential for INOVIQ's innovations.

Executive insights on successful study

We are thrilled with the results of this validation study, which highlight the test's remarkable accuracy in detecting early-stage ovarian cancer,' said Professor Carlos Salomon Gallo. 'The collaboration with the University of Queensland has been crucial in achieving these outcomes.' Dr. Leearne Hinch, CEO of INOVIQ, added, 'This study is a critical step towards commercializing the EXO-OC test.' Chairman David Williams emphasized, 'These findings pave the way for a potentially groundbreaking commercial product.